Limbaro, Jaxey .

HRN: 25-77-67  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/24/2024
AMPICILLIN 500MG (VIAL)
08/24/2024
08/30/2024
IVT
200mg
Q12
Pneumonia
Waiting Final Action 
08/24/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/24/2024
08/30/2024
IVT
40mg
OD
Pneumonia
Waiting Final Action 
08/27/2024
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
08/27/2024
09/02/2024
IVT
22mg
Q24
Sepsis
Waiting Final Action 
08/29/2024
CEFTAZIDIME 1GM (VIAL)
08/29/2024
09/04/2024
IV
110mg
Q8
Sepsis
Waiting Final Action 
09/02/2024
AZITHROMYCIN 200MG/5ML, 15ML SUSPENSION (SUSP)
09/02/2024
09/07/2024
PO
1ml
Q24hours
Neonatal Sepsis
Waiting Final Action 
02/13/2026
CEFTRIAXONE 1G (VIAL)
02/13/2026
02/20/2026
IV
200mg
Q12
Scaf Burn
Checking Initial Appropriateness 
02/13/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/13/2026
02/20/2026
TOPICAL
25g
OD
Scald Burn
Checking Initial Appropriateness 
02/16/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/16/2026
02/22/2026
TOPICAL
Generous Amount
OD
2nd Degree Burn
Checking Initial Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: